Drug Manufacturers Settle with State of California Over Antitrust Allegations

July 31, 2019

Two drugmakers have agreed to pay California a nearly $70 million settlement over allegations they violated antitrust laws by keeping generics off the market. A third drugmaker will be subject to an eight-year injunction. 

Teva Pharmaceuticals, Endo Pharmaceuticals, and Teikoku Pharma all engaged in “pay-for-delay” agreements to keep generics off the market and maintain monopolies over certain brand name drugs. This type of agreement is not always illegal, but when used in certain ways can violate antitrust laws. 

Read the full story from the LA Times.